Literature DB >> 25161385

Practical issues with high dose methotrexate therapy.

Osama M Al-Quteimat1, Mariam A Al-Badaineh1.   

Abstract

Methotrexate (MTX) is an antifolate cytotoxic medication used to treat certain types of cancer and at lower doses for rheumatic diseases. MTX has many serious adverse effects, such as myelosuppression, hepatic, renal and pulmonary disorders. For safe and effective use of high dose methotrexate (HDMTX) certain precautions should be followed. We present this case study with short review to briefly summarize the important practical issues related to HDMTX therapy.

Entities:  

Keywords:  Chemotherapy; Drug interaction; Methotrexate

Year:  2014        PMID： 25161385      PMCID： PMC4142365          DOI： 10.1016/j.jsps.2014.03.002

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN： 1319-0164            Impact factor:   4.330


  12 in total

1.  Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions.

Authors:  M A Kielhofner
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.

Authors:  Shewit Bezabeh; Ann Corken Mackey; Paul Kluetz; Dilara Jappar; Joyce Korvick
Journal:  Oncologist       Date:  2012-04-03

Review 3.  Methotrexate: clinical pharmacology, current status and therapeutic guidelines.

Authors:  W A Bleyer
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

Review 4.  Current treatment of osteosarcoma.

Authors:  W S Ferguson; A M Goorin
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

Review 5.  Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination.

Authors:  O M Al-Quteimat; M A Al-Badaineh
Journal:  J Clin Pharm Ther       Date:  2013-03-22       Impact factor: 2.512

Review 6.  The pharmacology of methotrexate.

Authors:  E A Olsen
Journal:  J Am Acad Dermatol       Date:  1991-08       Impact factor: 11.527

7.  Methotrexate nephrotoxicity.

Authors:  R M Fox
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1979

8.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

Authors:  S A Jacobs; R G Stoller; B A Chabner; D G Johns
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

Review 9.  Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review.

Authors:  Alexandra N Colebatch; Jonathan L Marks; Désirée M van der Heijde; Christopher J Edwards
Journal:  J Rheumatol Suppl       Date:  2012-09

10.  Glucarpidase to combat toxic levels of methotrexate in patients.

Authors:  Jacalyn M Green
Journal:  Ther Clin Risk Manag       Date:  2012-11-22       Impact factor: 2.423
View more
  4 in total

1.  Enhanced antitumor efficacy of poly(D,L-lactide-co-glycolide)-based methotrexate-loaded implants on sarcoma 180 tumor-bearing mice.

Authors:  Li Gao; Lunyang Xia; Ruhui Zhang; Dandan Duan; Xiuxiu Liu; Jianjian Xu; Lan Luo
Journal:  Drug Des Devel Ther       Date:  2017-10-20       Impact factor: 4.162

2.  Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.

Authors:  Jyoti Bajpai; Arun Chandrasekharan; Vijai Simha; Vikas Talreja; Ashay Karpe; Nikihil Pandey; Ashish Singh; Bharat Rekhi; Tushar Vora; Jaya Ghosh; Shripad Banavali; Sudeep Gupta
Journal:  J Glob Oncol       Date:  2018-09

3.  A Rapidly Fatal Case of Low-Dose Methotrexate Toxicity.

Authors:  Nasreen Shaikh; Muhammad Sardar; Rishi Raj; Punit Jariwala
Journal:  Case Rep Med       Date:  2018-06-13

4.  Acute Kidney Injury Following High-Dose Methotrexate Administration in a Day Care Hospital.

Authors:  Srimanta Chandra Misra; Alberto Santagostino; Gerard Dine; Larence Bonhomme Faivre
Journal:  Drug Saf Case Rep       Date:  2019-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.